Vigil Neuroscience — Technical Presentation (November 2022)
20 slides from Vigil Neuroscience's technical presentation, Nov 2, 2022
Slide 1: VGL101 Phase 1 Interim Topline Data Results in Healthy Volunteers
Vigil Neuroscience VGL101 Phase 1 Interim Topline Data Results in Healthy Volunteers November 2, 2022 Exhibit 99.2
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking statements,” which are made pursuant to the safe harbor provisions of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact may be d
Slide 3: Opening Remarks
Opening Remarks Ivana Magovcevic-Liebisch, President & CEO
Slide 4: Vigil's Mission: Restoring Microglial Vigilance
Vigil’s Mission: Restoring Microglial Vigilance to Create Disease-Modifying Treatments for Neurodegenerative Diseases Discovering and developing novel therapeutics designed to leverage microglial biology breakthroughs that activate and restore microglial function Precision-based development strategy
Slide 5: Vigil TREM2 Agonists: Differentiated Strategy & Multiple Modalities
Vigil TREM2 Agonists: Differentiated Strategy & Multiple Modalities TREM2 mAb in Development for ALSP: VGL101 Small Molecule TREM2 Agonist in Development for Larger Indications The ONLY targeted drug candidate in development for ALSP The ONLY TREM2 small molecule agonist in development Vigil Neurosc
Slide 6: VGL101 – Antibody Agonist of TREM2 with a Compelling Profile
VGL101 – Antibody Agonist of TREM2 with a Compelling Profile Human mAb: high TREM2 selectivity; sub-nanomolar potency Induces genes specific for microglia identity & function in CNS Brain penetration with dose-dependent PK, favorable half-life & CNS target engagement Preclinical proof of concept dem
Slide 7: VGL101 Interim Topline Phase 1 Results in Healthy Volunteers
VGL101 Interim Topline Phase 1 Results in Healthy Volunteers Spyros Papapetropoulos, Chief Medical Officer
Slide 8: Trial Design: VGL101 Phase 1 SAD/MAD in Healthy Volunteers
10 mg/kg n = 7 (5:2) 20 mg/kg n = 9 (6:3) 30 mg/kg n = 7 (6:1) 60 mg/kg n = 8 (6:2)1 3 mg/kg n = 8 (6:2) 1 mg/kg n = 8 (6:2) 40 mg/kg n = 8 (6:2) Trial Design: VGL101 Phase 1 SAD/MAD in Healthy Volunteers Single Ascending Doses (SAD) of VGL101; 1 Infusion Total Multiple Ascending Doses (MAD) of VGL1
Slide 9: VGL101 Demonstrated Favorable Safety & Tolerability Profile
VGL101 Demonstrated Favorable Safety & Tolerability Profile at Doses up to 40 mg/kg SAD and 20 mg/kg MAD* 82 healthy volunteers have been dosed in the ongoing first-in-human Phase 1 SAD/MAD trial 68 subjects received VGL101 14 subjects received placebo In blinded interim safety review of completed c
Slide 10: VGL101 Has Well-Characterized Linear & Dose Proportional PK
VGL101 Has Well-Characterized Linear & Dose Proportional PK Single Ascending Dose Pharmacokinetics (PK) 1 3 10 20 30* Dose (mg/kg) As of October 7, 2022 *Data on 30 mg/kg dose available for up to 28 days post-dose. Terminal data not yet available. © Vigil Neuroscience, Inc. 2022. All rights reserved
Slide 11: VGL101 Has Predictable PK with Repeat Dosing
VGL101 Has Predictable PK with Repeat Dosing ~27 days half-life supporting monthly dosing interval Brain penetration and achieving projected CSF therapeutic exposures 0.1 – 0.2% CSF-to-serum ratio 20 mg/kg Multiple Dose PK (3 doses at 28-day intervals; n=12) Nominal Time After First Dose (days) Mean
Slide 12: Proof of Target Engagement: Durable sTREM2 Decreases
Proof of Target Engagement: VGL101 Has Dose Dependent, Robust & Durable sTREM2 Decreases Hours Post 3rd/Final Dose 0 -300 -600 -900 -1,200 48 672 Change from Baseline pg/ml (±SEM) in sTREM2 Hours Post Single Dose 48 336 0 -300 -600 -900 -1,200 Change from Baseline pg/ml (±SEM) in sTREM2 Single Ascen
Slide 13: Proof of Target Engagement: sTREM2 Percent Change
Single Ascending Doses 20 mg/kg Multiple Dose (3 doses at 28-day intervals; n=6) Proof of Target Engagement: VGL101 Has Dose Dependent, Robust & Durable sTREM2 Decreases * * Hours Post Single Dose 10 5 0 -5 -10 -15 -20 -25 -30 % Change from Baseline (±SEM) in sTREM2 Baseline 48 336 Hours Post 3rd/Fi
Slide 14: Proof of Pharmacology: VGL101 Shows Durable sCSF1R Increases
Proof of Pharmacology: VGL101 Shows Durable sCSF1R Increases 20,000 15,000 10,000 5,000 0 -5,000 Change from Baseline pg/ml (±SEM) in sCSF1R 48 336 Hours Post Single Dose Change from Baseline pg/ml (±SEM) in sCSF1R 48 672 20,000 15,000 10,000 5,000 0 -5,000 Hours Post 3rd/Final Dose Single Ascending
Slide 15: Proof of Pharmacology: sCSF1R Percent Change
Proof of Pharmacology: VGL101 Shows Durable sCSF1R Increases Hours Post 3rd/Final Dose Baseline * 20 15 10 5 0 -5 48 672 % Change from Baseline (±SEM) in sCSF1R Baseline 20 15 10 5 0 -5 % Change from Baseline (±SEM) in sCSF1R Hours Post Single Dose 48 336 Single Ascending Doses 20 mg/kg Multiple Dos
Slide 16: In Summary
In Summary VGL101 was generally safe and well-tolerated at doses up to 40 mg/kg SAD and 20 mg/kg MAD VGL101 PK shows linear, predictable characteristics across doses and a half-life supports monthly dosing VGL101 demonstrated proof of target engagement and pharmacological activity based on dose depe
Slide 17: MG ea vigilant for your —
oa MG ea vigilant for your — elt O75 ~~ a . \ . - be —
Slide 18: 2022–2023 Anticipated Milestones
2022–2023 Anticipated Milestones Initiate Phase 2 portion of the Phase 2/3 clinical trial with VGL101 in ALSP Announce topline data for Phase 1 clinical trial with VGL101 in healthy volunteers* Submit IND and initiate clinical development for small molecule TREM2 agonist Q4 2022 Q4 2022 2023 Establi
Slide 19: your
your | ant for vigil
Slide 20: Thank You
Thank You
Vigil Neuroscience — Technical Presentation (November 2022) on 6ix